- Home
- PRZO vs ALXO Comparison
PRZO vs ALXO Comparison
Compare PRZO & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- ALXO
- Stock Information
- Founded
- PRZO 2014
- ALXO 2015
- Country
- PRZO Israel
- ALXO United States
- Employees
- PRZO N/A
- ALXO N/A
- Industry
- PRZO
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- PRZO
- ALXO Health Care
- Exchange
- PRZO Nasdaq
- ALXO Nasdaq
- Market Cap
- PRZO 20.1M
- ALXO 24.0M
- IPO Year
- PRZO 2023
- ALXO 2020
- Fundamental
- Price
- PRZO $1.35
- ALXO $0.46
- Analyst Decision
- PRZO
- ALXO Strong Buy
- Analyst Count
- PRZO 0
- ALXO 6
- Target Price
- PRZO N/A
- ALXO $3.30
- AVG Volume (30 Days)
- PRZO 1.7M
- ALXO 627.6K
- Earning Date
- PRZO 03-21-2025
- ALXO 08-07-2025
- Dividend Yield
- PRZO N/A
- ALXO N/A
- EPS Growth
- PRZO N/A
- ALXO N/A
- EPS
- PRZO N/A
- ALXO N/A
- Revenue
- PRZO $932,154.00
- ALXO N/A
- Revenue This Year
- PRZO N/A
- ALXO N/A
- Revenue Next Year
- PRZO N/A
- ALXO N/A
- P/E Ratio
- PRZO N/A
- ALXO N/A
- Revenue Growth
- PRZO 50.22
- ALXO N/A
- 52 Week Low
- PRZO $0.49
- ALXO $0.40
- 52 Week High
- PRZO $3.16
- ALXO $8.78
- Technical
- Relative Strength Index (RSI)
- PRZO 61.79
- ALXO 46.05
- Support Level
- PRZO $1.12
- ALXO $0.40
- Resistance Level
- PRZO $1.30
- ALXO $0.46
- Average True Range (ATR)
- PRZO 0.10
- ALXO 0.04
- MACD
- PRZO 0.00
- ALXO -0.00
- Stochastic Oscillator
- PRZO 78.79
- ALXO 35.90
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.